Prohost Biotech – Exclusive Biotech Research

Exclusive Market Insight

& Scientific analysis

  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Menu
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us
Home
Today’s Highlights
Exelixis Has Good News Today and More is Expected

Exelixis Has Good News Today and More is Expected

Today’s Highlights October 19, 2020

Exelixis and Bristol-Myers Squibb sNDA and sBLA Accepted by the FDA
Exelixis (EXEL) and Bristol-Myers Squibb (This content is for paid subscribers.

Please click here to subscribe or here to log in.
Today’s Highlights
Bristol-Myers Squibb (BMY), Exelixis (EXEL)
October 19, 2020
Tweet Pin It

Other Articles

  • Regeneron: The Completed Acquisition of Checkmate Pharmaceuticals is Excellent News Not Bad News
    May 31, 2022 0
  • Karyopharm Therapeutics: CHMP Recommended Approval of the Firm’s Product NEXPOVIO® for Multiple Melanoma in Europe.
    May 20, 2022 0
  • Vertex Provided Successful Results of VX-880 for Type 1 Diabetes Then Placed the Product on Clinical Hold
    May 2, 2022 0
  • Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings
    April 27, 2022 0

Search ProhostBiotech

Popular Links

Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)
  • Recent

ProhostBiotech Archive

Sign Up for Weekly Emails

Prohost Biotech – Exclusive Biotech Research Copyright © 2022.
© 2014 Prohost Biotech. All rights reserved.

Privacy Policy | Cancellation Policy | Forward Looking Statement